Horizon Discovery Biosciences LIMITED

Horizon Discovery Biosciences LIMITED, a Cambridge, United Kingdom-based foreign-owned manufacturer of genetic research reagents and libraries, supplies specialized siRNA, shRNA, and CRISPR screening materials to federal biomedical research agencies as a prime contractor exclusively, with 19 purchase orders totaling $874 thousand across a five-year span. The vendor operates full-and-open (non-set-aside), reflecting its status as a large foreign business subsidiary of Revvity Inc., a medical imaging provider. Horizon Discovery holds no parent IDIQs, GWACs, or BPAs and does not subcontract.

Customer concentration at Horizon Discovery is extreme. The National Center for Advancing Translational Sciences (NCATS) within NIH anchors the footprint at 58% of all awards by count and 68% of combined potential value ($590 thousand across 11 purchase orders). The Defense Health Agency holds the second-largest share at 2 awards and $119 thousand, followed by the Army Medical Command at 2 awards and $69 thousand. Together, these three customers account for 95% of recent awards and 98% of combined potential value. The five-agency customer set reflects a tightly clustered intramural and translational research portfolio with minimal diversification.

Horizon Discovery's capability portfolio centers on genome-wide functional genomics libraries: ON-TARGET Plus siRNA pools targeting protein kinases and druggable genomes; CRISPRa (activation) and CRISPRko (knockout) synthetic sgRNA libraries in Echo 384 high-throughput screening formats; SMARTVector lentiviral shRNA pooled libraries; and Accell-modified siRNA reagents. Representative awards include a $202 thousand NCATS purchase order (January 2022) for siRNAs with Accell modification; a $122.6 thousand NCATS order (May 2023) for fourteen mouse ON-TARGET Plus siRNA libraries; and a $71.5 thousand Defense Health Agency order (August 2024) for siRNA genome libraries used in experimental system evaluation. A May 2026 Defense Health Agency purchase order for a human deconvolution library set ($47.9 thousand, completion May 29, 2026) and a September 2025 NIH Child Health and Human Development order for custom CRISPRa and CRISPRko sgRNA pool libraries ($43.1 thousand) exemplify the vendor's recent work in pooled and custom screening formats. The vendor operates under NAICS 325414 (Biological Product Manufacturing, except Diagnostic), with secondary activity in testing laboratories.

Activity has been sporadic: two awards in 2022, five in 2023, three in 2024, three in 2025, and one through May 2026. The vendor carries no recompete cliff; all awards are low-value purchase orders with firm completion dates, and the most recent award closed in May 2026. As a pure-play supplier of off-the-shelf and custom genomic reagent kits with no teaming footprint and no parent vehicle seats, Horizon Discovery operates transactionally within the intramural NIH research space with minimal access to broader federal procurement channels.